

Percent Tumor Volume Change
200
150
100
50
0
-100
-50
0
50
100
150
200
250
300
Days On Study
1st line: Vemurafenib treatment
2nd line:
Tumor re-growth while on 2nd line therapy
α-PDL1: 100%
MEKi: 67%
MEKi + α-PDL1: 0%

FIG. 1



Vemurafenib then α-PDL1 (n=3)
Vemurafenib then MEKi (n=6)
Vemurafenib then MEKi + α-PDL1 (n=7)
50
0
-50
-100
Percent change from crossover

FIG. 2